PERSEUS Trial Adverse Events and Safety Profiles
Brea C. Lipe, MD explains common grade 3 and grade 4 adverse events observed in the PERSEUS trial.
Summary
In terms of safety, the PERSEUS trial did not reveal any new or unexpected adverse events. The most common side effects were thrombocytopenia and neutropenia, consistent with the known safety profile of Dara-VRd which tends to have higher rates of cytopenia compared to VRd alone. Notably, this trial was conducted during the COVID-19 pandemic. Higher rates of infectious complications like pneumonia were seen in the Dara-VRd arm compared to VRd alone. This reinforces our understanding that quadruplets can increase susceptibility to infections, though we are learning how to better mitigate these risks. Overall, the safety profile aligned with expectations for Dara-VRD, with managing cytopenia and infections as key considerations.
Summary was AI-generated and edited for clarity.
Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab
November 18th 2024During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.
Read More
